Jim Woody

Chief Executive Officer

James N. Woody, M.D., Ph.D has more than 25 years of pharmaceutical research and management expertise.

He has served as our Chief Executive Officer and as a director since the closing of the business combination in November 2020. Dr. Woody has served as the CEO of 180 since July 2020, and as a director of 180 Life Sciences since September 2020.

Dr. Woody was a founder and served as Chairman of the Board of Directors for Viracta Pharmaceuticals, a lymphoma therapeutic company (2014 to 2020). With the company undergoing a reverse merger into a public company, he resigned his Board member position and continues as a Board observer.

He has served in a variety of health and management roles including as President of Roche Bioscience, and CSO and Senior Vice President of R&D for Centocor.

At Centocor, Jim was part of the team that discovered Remicade, used to treat arthritis and which is now one of the best-selling drugs in the world.

He served as Commanding Officer and Director at the US Naval Medical Research and Development Command in Bethesda, Maryland.

In this role he was responsible for the surveillance, detection and therapy for all biologic warfare agents and infectious diseases in the First Gulf War; he was awarded the US Navy Legion of Merit for his service.

He holds an MD from Loma Linda University, and trained in pediatric immunology at Duke University and Boston Children’s Hospital (Harvard).

He further holds a PhD in Immunology from the University of London and has co-authored more than 140 publications.

Quan A. Vu

Chief Operating Officer

Quan Vu brings more than 20 years of “hands-on” healthcare business executive experience with an emphasis on corporate & business development, strategy, finance and operations. He possesses a demonstrated history of prospecting, evaluating, structuring and closing transactions that augment both organizational and shareholder value. He’s also a strategist with a sound understanding of pipeline development, commercial assessment and go-to-market strategies. An adept finance professional, Quan has consummated billions of dollars in capital raises and M&A deals for public and private companies. He’s also an operator proficient at navigating complex situations, identifying improvement opportunities and propelling enterprise-wide changes to optimize performance.

In the past two years prior to joining 180 Life Sciences, Quan held several concurrent leadership roles. He served as the CEO of Baleena Bioscience, a consolidator of several healthspan biotechnology/medical device assets with the express purpose of going public via a SPAC. Additionally, he served as a Managing Director and Co-Head of Healthcare IT for Solganick & Co., a boutique technology investment bank providing M&A advisory. He also provided interim CFO/CBO consulting services, including private capital raises and out-licensing, as a member of LS Associates, a division of LifeSci Partners.

Before his roles above, Quan served as Vice President of Strategy & Corporate/Business Development at Opiant Pharmaceuticals, a public company focused on addiction and drug overdose, where he directly facilitated the company’s growth from 3 to 16 FTEs and from $10M to $60M market capitalization in under three years. Prior to Opiant, he served as a Staff Vice President at Anthem with responsibilities for strategy, planning and administration, including the management of a $2.2B IT budget. Prior to Anthem, he held leadership roles at Impax Laboratories and Amgen as a Director and Senior Manager, respectively, with responsibilities that encompassed strategy, corporate/business development and finance.

Quan began his career in financial and economic consulting at LECG and in healthcare corporate finance and M&A at bulge-bracket investment banks, including Morgan Stanley and Goldman Sachs. He obtained his BA in Economics from UCLA, graduating summa cum laude with College Honors and Economics Departmental Honors. He is also a Certified Treasury Professional (inactive).

Dr Jonathan Rothbard

Chief Scientific Officer

Dr Jonathan Rothbard works in the neurology department at Stanford University.

Dr Rothbard headed the Molecular Immunology Laboratory at the Imperial Cancer Research Fund in London in 1990, where he first worked with Professor Sir Marc Feldmann.

He has collaborated with Professor Lawrence Steinman since 1986, when they published the first of their 26 manuscripts together.

Dr Rothbard has been involved at a high level with start-up pharmaceuticals discovery; in 1987 he founded Amylin in San Diego and has also founded start-ups CellGate and ImmuLogic.

Amylin was focused on the discovery, development and commercialization of drugs treating diseases including diabetes and obesity.

The company was sold in 2012 to Bristol-Myers Squibb for $5.4 billion.

In addition to neurology, Dr Rothbard has also worked in the departments of chemistry and rheumatology at Stanford University.

Dr Rothbard holds a BA from Hamilton College and a PhD from Columbia University, which he followed with a fellowship at The Rockefeller University.

Prof Jagdeep Nanchahal

Head of Clinical Advisory Board

Professor Nanchahal is a surgeon scientist at the University of Oxford, focused on defining the molecular mechanisms of common diseases such as fibrosis and translating his findings through to early phase clinical trials

His surgical background has allowed him to bring a unique insight to common, yet relatively neglected diseases

Many of his findings stem from investigations in primary human tissues, rather than relying on animal models that often fail to recreate human clinical conditions

He has pioneered the treatment of fibrosis of the hand (Dupuytren’s disease), which unlike fibrosis in major human tissues can be diagnosed early and samples easily obtained to discover new pathways of importance

In 2013 his group identified TNF⍺ as a target for Dupuytren’s disease, leading to a phase 2a clinical trial to determine the effective dose and preparation of anti-TNF

Ozan Pamir

Chief Financial Officer

Ozan has played a key role in the formation of 180 Life Sciences as the CFO of two of the subsidiaries since late 2018 and oversaw the merger of 180 Therapeutics, Katexco and Cannbiorex, which now form 180 Life Sciences. He was instrumental in completing the company’s NASDAQ listing and managed majority of the funding rounds for the company.

Throughout his career, Ozan has specialized in helping companies in defining their corporate strategy, and executing corporate transactions such as M&As and IPOs. He brings a wealth of knowledge and experience to the 180 Life Sciences team as a former investment banker with in-depth capital markets expertise. Ozan was previously VP of Investment Banking at a leading Canadian independent investment bank, where he co-founded the origination department which focused on small and mid-cap financing and advisory mandates. In this role he advised private and public companies on M&A deals and was the lead banker on more than 30 financings, raising approximately $400 million.

After his investment banking career, Ozan has worked with early stage biotech companies as CFO and/or a board member. Ozan was the CFO of Enosi Life Sciences and the CFO and a board member of Unify Pharmaceuticals, both pre-clinical companies focused on autoimmune diseases.

Ozan holds an Economics and Finance degree from McGill University and is a CFA Charterholder.

Fiona McCann

Scientific Director

Fiona McCann PhD is an immunologist and has held the role of Scientific Director at 180 Life Sciences in UK since September 2018. 

Fiona has obtained her PhD from studies at Pfizer and University of Kent, UK in 2000. 

Since then she has carried out translational research at Imperial College London, and Kennedy Institute of Rheumatology (KIR), and has published several high impact studies with pharmaceutical companies (including Bayer Schering, Celgene, GSK) which unravel novel mechanisms of immune regulation, harnessing potential for therapeutic discovery. 

From 2011-2018, she was group leader for therapeutic target discovery in autoimmune disease and fibrosis at University of Oxford, firstly working with NovoNordisk, and secondly with a multi-national consortium of academics and pharma at KIR/SGC Oxford (EU/IMI funded). 

She holds a mini-MBA from SAID Business School, University of Oxford, a certificate in Entrepreneurs in Clinical Academia (ECA/FOCIS) from INSEAD business school, Fontainebleau, France and is currently studying towards a certificate in Project Management in Biotech at University of Washington and UCSD, due to complete June 2021.